1	The role of COVID-19 vaccines in preventing post COVID-19
2	thromboembolic and cardiovascular complications: a multinational
3	cohort study
4	
5	Author list
6	Núria Mercadé-Besora ^{1,2,3} , BA, nmercade@idiapjgol.org
7	Xintong Li ¹ , MSc, xintong.li@ndorms.ox.ac.uk
8	Raivo Kolde, PhD ⁴ , raivo.kolde@ut.ee
9	Nhung TH Trinh, PhD ⁵ , nhung.trinh@farmasi.uio.no
10	Maria T. Sanchez-Santos, MSc ¹ , maria.sanchez@ndorms.ox.ac.uk
11	Wai Yi Man, MSc ¹ , waiyi.man@ndorms.ox.ac.uk
12	Elena Roel, PhD ³ , eroel@idiapjgol.org
13	Carlen Reyes ³ , creyes@idiapjgol.org
14	Antonella Delmestri, PhD ¹ , antonella.delmestri@ndorms.ox.ac.uk
15	Hedvig ME Nordeng, PhD ^{5,6} , h.m.e.nordeng@farmasi.uio.no
16	Anneli Uusküla, PhD ⁷ , anneli.uuskula@ut.ee
17	Talita Duarte-Salles, PhD ^{3,8} , tduarte@idiapjgol.org
18	Clara Prats, PhD ² , clara.prats@upc.edu
19	Daniel Prieto-Alhambra, PhD ^{1,8,9} , daniel.prietoalhambra@ndorms.ox.ac.uk
20	Annika M Jödicke, PhD* ¹ , annika.jodicke@ndorms.ox.ac.uk
21	Martí Català, PhD* ¹ , <u>marti.catalasabate@ndorms.ox.ac.uk</u>
22	

- 23 ¹ Pharmaco- and Device Epidemiology Group, Health Data Sciences, Botnar Research Centre, NDORMS, University of
- 24 Oxford, United Kingdom
- 25 ² Department of Physics, Universitat Politècnica de Catalunya, Barcelona, Spain
- 26 ³ Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGOI),
- 27 Barcelona, Spain
- 28 ⁴ Institute of Computer Science, University of Tartu, Tartu, Estonia
- 29 ⁵ Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and
- 30 Natural Sciences, University of Oslo, Oslo, Norway
- 31 ⁶ Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway
- 32 ⁷ Department of Family Medicine and Public Health, University of Tartu, Tartu, Estonia
- 33 ⁸ Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
- 34 ⁹Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
- 35
- 36 *MC and AMJ share senior authorship
- 37 Corresponding author:
- 38 Prof. Daniel Prieto-Alhambra
- 39 Botnar Research Centre, Windmill Road, OX3 7LD, Oxford, United Kingdom
- 40
- 41 <u>Word count: 3000</u>
- 42

43 Key Points

44 Question

- 45 What is the impact of COVID-19 vaccination to prevent cardiac complications and
- 46 thromboembolic events following a SARS-CoV-2 infection?

47 Findings

- 48 Results from this multinational cohort study showed that COVID-19 vaccination reduced risk
- 49 for acute and subacute COVID-19 heart failure, as well as venous and arterial
- 50 thromboembolic events following SARS-CoV-2 infection.

51 Meaning

- 52 These findings highlight yet another benefit of vaccination against COVID-19, and support
- 53 the recommendations for COVID-19 vaccination even in people at high cardiovascular risk.

54 Abstract

55 Importance

- 56 The overall effects of vaccination on the risk of cardiac, and venous and arterial
- 57 thromboembolic complications following COVID-19 remain unclear.

58 Objective

- 59 We studied the association between COVID-19 vaccination and the risk of acute and
- 60 subacute COVID-19 cardiac and thromboembolic complications.

61 Design

62 Multinational staggered cohort study, based on national vaccination campaign rollouts.

63 Setting

Network study using electronic health records from primary care records from the UK,
primary care data linked to hospital data from Spain, and national insurance claims from
Estonia.

67 Participants

- All adults with a prior medical history of \geq 180 days, with no history of COVID-19 or previous
- 69 COVID-19 vaccination at the beginning of vaccine rollout were eligible.

70 Exposure

- 71 Vaccination status was used as a time-varying exposure. Vaccinated individuals were
- 72 classified by vaccine brand according to the first dose received.

73 Main Outcomes

Post COVID-19 complications including myocarditis, pericarditis, arrhythmia, heart failure
(HF), venous (VTE) and arterial thromboembolism (ATE) up to 1 year after SARS-CoV-2
infection.

77 Measures

Propensity Score overlap weighting and empirical calibration based on negative control outcomes were used to minimise bias due to observed and unobserved confounding, respectively. Fine-Gray models were fitted to estimate sub-distribution Hazard Ratios (sHR) for each outcome according to vaccination status. Random effect meta-analyses were conducted across staggered cohorts and databases.

83 Results

Overall, 10.17 million vaccinated and 10.39 million unvaccinated people were included. Vaccination was consistently associated with reduced risks of acute (30-day) and subacute post COVID-19 VTE and HF: e.g., meta-analytic sHR 0.34 (95%CI, 0.27-0.44) and 0.59 (0.50-0.70) respectively for 0-30 days, sHR 0.58 (0.48 - 0.69) and 0.71 (0.59 - 0.85) respectively for 90-180 days post COVID-19. Additionally, reduced risks of ATE, myocarditis/pericarditis and arrhythmia were seen, but mostly in the acute phase (0-30 days post COVID-19).

90 Conclusions

91 COVID-19 vaccination reduced the risk of post COVID-19 complications, including cardiac
92 and thromboembolic outcomes. These effects were more pronounced for acute (1-month)
93 post COVID-19 outcomes, consistent with known reductions in disease severity following
94 breakthrough vs unvaccinated SARS-CoV-2 infection.

95 Relevance

- 96 These findings highlight the importance of COVID-19 vaccination to prevent cardiovascular
- 97 outcomes after COVID-19, beyond respiratory disease.

99 Keywords

- 100 Subacute COVID-19 complications
- 101 Pharmacoepidemiology
- 102 Public health
- 103 Cohort study
- 104 COVID-19 vaccines
- 105 Cardiovascular diseases

107 Introduction

108	COVID-19 vaccines were approved under emergency authorisation as from December 2020.
109	They showed high effectiveness against SARS-CoV-2 infection, COVID-19 related
110	hospitalisation and death (1–5). Nonetheless, concerns were raised after research findings
111	suggested a potential association between adenovirus -based COVID-19 vaccines and
112	unusual thromboembolic events (6–10). More recently, mRNA -based vaccines were found
113	to be associated with risk of rare myocarditis events, especially among male teenagers and
114	young adults (11–16).
115	On the other hand, it is well-known that SARS-CoV-2 infection can trigger cardiac and
116	thromboembolic complications (17–19). Previous studies have showed that while slowly
117	decreasing over time, risk for serious complications remain high for up to a year after
118	infection (20,21). While acute and subacute cardiac and thromboembolic complications
119	following SARS-CoV-19 are rare, they present a substantial burden to the affected patients.
120	Given the global extension of the pandemic, the absolute number of cases could become
121	substantial.
122	Recent studies suggest that COVID-19 vaccination could potentially protect against cardiac
123	and thromboembolic complications attributable to COVID-19 (22–24). However, most of
124	those focussed on relatively short-term complications (up to 30 (22) and 180 (23) days after
125	infection) and were conducted in specific populations (ambulatory infections (22) and US
126	Veterans (23)).
127	Evidence is still scarce to whether the additive effect of COVID-19 vaccines protecting 1)
128	against SARS-CoV-2 infection and 2) reducing post COVID-19 cardiac and thromboembolic

129 outcomes, outweighs any risks of these complications potentially associated with

130 vaccination.

- 131 We leveraged large representative data sources from 3 European countries to assess the
- 132 overall effect of COVID-19 vaccines on the risk of acute and subacute post COVID-19
- 133 complications including venous thromboembolism (VTE), arterial thromboembolism (ATE),
- and cardiac events. Additionally, we studied the comparative effects of ChAdOx1 (adenovirus
- -based) vs BNT162b2 (mRNA -based) on the risk of these same outcomes.

136

137 Methods

138 Data Sources

We used four routinely-collected population-based healthcare datasets from three Europeancountries: the UK, Spain, and Estonia.

141 For the UK, we utilized data from two primary care databases, namely Clinical Practice

142 Research Datalink, CPRD AURUM (25) and CPRD GOLD (26), which currently cover 3.1 million

and 13 million active participants, respectively. Additionally, Spanish data was provided by

- 144 the Information System for Research in Primary Care (SIDIAP) (27) which encompasses
- primary care records from around 75% of the population in the region of Catalonia, and it

146 was linked to hospital admissions data (Conjunt Mínim Bàsic de Dades d'Alta Hospitalària).

147 Finally, the CORIVA cohort was retrieved from the Estonian national health insurance claims

database, covering around 440 thousand participants consisting of a random sample of the

149 population plus all COVID-19 cases identified during the first year of the pandemic. CORIVA

150 was linked to death registry and all COVID-19 testing from the national health information

151 system.

152 Databases included socio-demographic information, diagnoses, measurements,

- 153 prescriptions, and secondary care referrals. Further, all databases were linked to vaccine
- registries, including records of all administered vaccines from all healthcare settings. Data
- availability for CPRD GOLD ended in 12/2021, AURUM in 01/2022, SIDIAP in 06/2022, and
- 156 CORIVA in 12/2022.
- 157 All four databases were mapped to the Observational Medical Outcomes Partnership
- 158 (OMOP) Common Data Model (CDM) (28) to facilitate federated analytics.

159 Multinational network staggered cohort study: Study design and participants

- 160 The study considered vaccination as a time-varying exposure using a staggered cohort
- design. Vaccine rollout phases were grouped in four different stages, each one with country-
- 162 specific dates and inclusion criteria.
- 163 Source population comprised all adults registered in the respective database for at least 180
- days at the start of the study (04/01/2021 for CPRD GOLD and AURUM, 20/02/2021 for
- 165 SIDIAP, and 28/01/2021 for CORIVA). Subsequently, each staggered cohort included
- 166 individuals eligible for vaccination during the enrolment period who were not previously
- 167 vaccinated against or infected with SARS-CoV-2. Cohort 1 enrolled elderly population,
- 168 whereas cohort 2 comprised individuals at risk for severe COVID-19. Cohort 3 comprised
- 169 people aged \geq 40, and cohort 4 included predominantly younger people (\geq 18).
- 170 People receiving a first vaccine dose within enrolment period were allocated to the
- vaccinated cohort (VC), and their index date was the date of the first vaccine dose.
- 172 Individuals who did not receive a vaccine dose comprised the unvaccinated cohort (UVC),
- and their index date was sorted within enrolment period, based on the distribution of index
- dates in the VC. Individuals infected with SARS-CoV-2 before index date were excluded.

- 175 Follow-up of individuals was until the earliest of: end of available data, death, change in
- 176 exposure status (first vaccine dose for UVC), or outcome of interest.
- 177 Supplementary Figures S1-2 and Table S1 provide more details on cohort definitions,
- 178 enrolment periods and inclusion criteria for each country. The proposed staggered cohort
- 179 study design was used in previous work and is published in detail elsewhere (29).
- 180 COVID-19 vaccination
- 181 All vaccines approved within study periods from 01/2021 to 07/2021, namely ChAdOx1
- 182 [Oxford/AstraZeneca], BNT162b2 [BioNTech/Pfizer], Ad26.COV2.S [Janssen], and mRNA-1273
- 183 [Moderna] were included for this study.

184 **Post COVID-19 outcomes of interest**


- 185 Outcomes of interest in the study were defined as a SARS-CoV-2 infection followed by a
- 186 record of a pre-defined thromboembolic or cardiac event of interest within a year after
- infection, in those individuals with no record of the same clinical event in the 6 months
- 188 before COVID-19. Outcome date was set as the corresponding SARS-CoV-2 infection date.
- 189 COVID-19 disease was identified from either a positive SARS-CoV-2 test (PCR/ antigen), or a
- clinical COVID-19 diagnosis, with no record of COVID-19 in the previous 6 weeks. This wash-
- 191 out period was imposed to identify "new" infections and exclude re-recordings of the same
- 192 COVID-19 episode.
- 193 Events of interest after COVID-19 were selected based on previous studies (21,22,30). These
- 194 were ischemic stroke (IS), haemorrhagic stroke (HS), transient ischemic attack (TIA),
- 195 ventricular arrhythmia or cardiac arrest (VACA), myocarditis or pericarditis (MP), myocardial
- 196 infarction (MI), heart failure (HF), pulmonary embolism (PE) and deep vein thrombosis
- 197 (DVT). We used two composite outcomes: 1) VTE, as an aggregate of PE and DVT, and 2)
- 198 ATE, as a composite of IS, TIA, and MI. To avoid re-recording of the same complication we

- imposed a wash-out period of 90 days between records. Phenotypes for these complications
- were based on previously published studies (31,32).
- 201 Further, outcomes were ascertained in four different time periods following SARS-CoV-2
- infection: the first period described the acute infection phase, i.e. 0 to 30 days after COVID-
- 19, whereas the later periods, i.e. 31 to 90 days, 91 to 180 days, and 181 to 365 days
- 204 illustrate the subacute phase (Figure 1).

Figure 1: Study outcome design. Study outcomes of interest are defined as a COVID-19 infection followed by one of the complications in the figure, within year after

infection. Outcomes were ascertained in four different time windows after SARS-CoV-2 infection: 0-30 days (namely the acute phase), 31-90 days, 91-180 days, and 181-365

207 days (these last three comprise the subacute phase).



209 Negative Control Outcomes

- 210 Negative control outcomes (NCO) refer to outcomes which investigators believe they are not
- associated (causal relation) with the exposure, and share the same causal or bias structure
- 212 with the exposure and outcome of interest (33). The expected occurrence of events should
- be similar in the compared cohorts, otherwise it may indicate a source of unobserved bias.
- The study used 43 different NCO from previous work assessing vaccine effectiveness (34,35)
- 215 to detect residual confounding.

216 Statistical analysis

217 Federated network analyses

A template for an analytical script was developed, and subsequently tailored to include the

219 country-specific aspects (e.g. dates, priority groups) for the vaccination rollout. The specific

220 R code was then executed locally in each database. Only aggregated data was shared and

221 person counts <5 were clouded.

222 Propensity Score Weighting

223 Large-Scale Propensity Scores (PS) were calculated to estimate the likelihood of a person to

receive the vaccine based on their demographic and health-related (e.g. conditions,

225 medication) characteristics prior to the index date. PS were then used to minimise observed

- 226 confounding by creating a weighted population (based on Overlap Weights (36)) in which
- individuals contributed with a different weight based on their PS and vaccination status.
- 228 Variables included in the PS comprised age, sex, location, index date, prior observation time
- in the database, number of previous outpatient visits, and previous SARS-CoV-2 PCR/antigen
- 230 tests. Regional vaccination, testing and COVID-19 incidence rates were also forced into PS
- equation for CPRD AURUM and GOLD (37) and SIDIAP (38). In addition, conditions and

232	prescriptions within 0-30 days, 31-180 days, and 181-anytime (latter window only for
233	conditions) before index date, with a prevalence of >0.5% and predictive of vaccination
234	based on LASSO regression, were included to the PS model.
235	PS were estimated for each staggered cohort and analysis separately. We considered that
236	covariate balance was achieved if Absolute Standardised Mean Differences (ASMD) were
237	≤0.1 after weighting (39). Baseline characteristics (e.g. age, sex, prior history, general health
238	conditions) were reported.
239	Effect estimation
240	To account for the competing risk of death associated with COVID-19, Fine-and-Gray models
241	(40) were utilized to calculate subdistribution Hazard Ratios (sHR). Subsequently, sHR and
242	confidence intervals were empirically calibrated from NCO estimates (41) to account for
243	unmeasured confounding.
244	For each outcome, treatment estimates from the four staggered studies were pooled using
245	random effect meta-analysis (42), both separately for each database and across all four
246	databases.
247	Sensitivity analysis
248	Sensitivity analyses were used to test the effect of two approaches in the main analysis: first,
249	we censored follow-up for vaccinated people at the time when they received their second
250	vaccine dose. Second, we captured only the first post COVID-19 outcome within the year
251	after infection. Supplementary Figure S3 depicts follow-up for the analyses.
252	Further, we compared vaccinated groups by vaccine brand, namely, BNT162b2 vs. ChAdOx1.
253	Data and code availability
254	All analytic code for the study is available at (<u>https://github.com/oxford-</u>
255	pharmacoepi/vaccineEffectOnPostCovidCardiacThromboembolicEvents). The repository also

- contains code lists for vaccines, COVID-19 tests and diagnoses, cardiac and thromboembolic
- 257 events, NCO, and health conditions to prioritize patients for vaccination in each country.
- 258 Analyses were conducted using R 4.2.3.

259

260 **Results**

- 261 All aggregated results are available via a web application (<u>https://dpa-pde-</u>
- 262 <u>oxford.shinyapps.io/PostCovidComplications/</u>).
- 263 We included over 10.17 million vaccinated individuals (1,618,395 from CPRD
- 264 GOLD; 5,729,800 from CPRD AURUM; 2,744,821 from SIDIAP and 77,603 from CORIVA), and
- 265 10.39 million unvaccinated (1,640,371; 5,860,564; 2,588,518 and 302,267, respectively).
- 266 Supplementary Figures S4-7 illustrate flowcharts in each database.
- 267 Adequate covariate balance was achieved after PS weighting in most studies: CORIVA (all
- cohorts) and SIDIAP (cohorts 1 and 4) did not contribute to ChAdOx1 sub-analysis due to
- sample size and covariate unbalance. ASMD results are accessible in the web application.
- 270 NCO analyses suggested residual bias despite PS weighting, with a majority of NCO
- associated positively with vaccination. Therefore, calibrated estimates are reported in this
- 272 manuscript. Uncalibrated effect estimates and NCO analyses are available in the web
- 273 interface.

274 **Population characteristics**

- 275 Table 1 presents baseline characteristics for the weighted populations in CPRD AURUM, for
- 276 illustrative purposes. Supplementary Tables S2-26 summarise baseline characteristics for
- 277 weighted and unweighted populations for each database and comparison. Across databases

- and cohorts, populations followed similar patterns: cohort 1 represented the eldest
- 279 population (around 80 years old) with predominant female population (60%). Age median
- lowered to 30-40 years in cohort 4, which was more balanced regarding sex. Overall,
- weighted populations showed adequate balance (ASMD < 0.1) in all baseline characteristics.

Table 1: Characteristics of weighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure

is any COVID-19 vaccine.

	С	ohort 1		С	ohort 2		С	ohort 3		Cohort 4			
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	
N (individuals)	154,864	154,245		420,707	420,931		463,495	462,463		818,917	827,124		
Age, median [Q25- Q75]	80 [76-84]	80 [76-84]	0.000	58 [44-67]	58 [44-67]	0.005	50 [41-58]	52 [40-58]	0.003	34 [26-42]	34 [26-42]	0.004	
Sex: Female, N(%)	88,349 (57%)	87,639 (57%)	0.005	248,156 (59%)	249,561 (59%)	0.006	245,248 (53%)	245,600 (53%)	0.004	351,435 (43%)	358,688 (43%)	0.009	
Years of prior history ^ª , median [Q25-Q75]	24 [10-35]	24 [10-36]	0.006	18 [8-29]	18 [8-29]	0.003	14 [6-24]	14 [7-24]	0.008	8 [4-17]	7 [3-18]	0.001	
Number visits, median [Q25-Q75]	10 [5-18]	10 [6-17]		8 [3-15]	8 [5-14]		4 [1-11]	6 [3-11]		2 [0-6]	2 [0-6]		
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		
Comorbidities ^b , N(%)													
Anxiety	23,200 (15%)	22,789 (15%)	0.006	94,390 (22%)	91,644 (22%)	0.016	92,820 (20%)	90,807 (20%)	0.010	123,055 (15%)	125,202 (15%)	0.003	
Asthma	16,978 (11%)	16,663 (11%)	0.005	95,770 (23%)	94,550 (22%)	0.007	79,642 (17%)	78,266 (17%)	0.007	63,687 (8%)	61,472 (7%)	0.013	
Chronic kidney disease	36,149 (23%)	36,046 (23%)	0.001	28,181 (7%)	29,756 (7%)	0.015	10,283 (2%)	10,577 (2%)	0.005	3,840 (0%)	3,572 (0%)	0.006	
COPD	13,385 (9%)	13,181 (9%)	0.003	17,447 (4%)	17,999 (4%)	0.006	6,062 (1%)	5,754 (1%)	0.006	1,901 (0%)	1,918 (0%)	0.000	
Dementia	9,483 (6%)	8,517 (6%)	0.026	4,182 (1%)	3,879 (1%)	0.007	1,361 (0%)	1,392 (0%)	0.001	276 (0%)	495 (0%)	0.012	
Depressive disorder	18,632 (12%)	18,547 (12%)	0.000	85,280 (20%)	81,945 (19%)	0.020	81,891 (18%)	79,804 (17%)	0.011	94,373 (12%)	97,053 (12%)	0.007	
Diabetes	29,365 (19%)	28,831 (19%)	0.007	49,408 (12%)	48,562 (12%)	0.006	26,616 (6%)	28,628 (6%)	0.019	12,787 (2%)	12,539 (2%)	0.004	

	С	ohort 1		С	ohort 2		С	ohort 3		С	ohort 4	
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
GERD	8,718 (6%)	8,515 (6%)	0.005	19,907 (5%)	18,924 (4%)	0.011	15,646 (3%)	14,982 (3%)	0.008	13,882 (2%)	13,893 (2%)	0.001
Heart failure	9,349 (6%)	8,851 (6%)	0.013	7,284 (2%)	6,502 (2%)	0.015	2,660 (1%)	2,470 (1%)	0.005	930 (0%)	816 (0%)	0.005
Hypertension	81,563 (53%)	80,806 (52%)	0.006	97,707 (23%)	98,193 (23%)	0.002	54,649 (12%)	55,798 (12%)	0.008	22,925 (3%)	24,450 (3%)	0.009
Hypothyroidism	15,125 (10%)	15,098 (10%)	0.001	25,579 (6%)	25,962 (6%)	0.004	17,162 (4%)	17,580 (4%)	0.005	12,427 (2%)	12,641 (2%)	0.001
Malignant neoplastic disease	33,467 (22%)	33,024 (21%)	0.005	30,194 (7%)	35,085 (8%)	0.043	14,815 (3%)	14,140 (3%)	0.008	6,447 (1%)	5,766 (1%)	0.011
Myocardial infarction	7,824 (5%)	7,731 (5%)	0.002	9,964 (2%)	11,319 (3%)	0.020	3,787 (1%)	3,664 (1%)	0.003	1,315 (0%)	1,069 (0%)	0.008
Osteoporosis	15,275 (10%)	15,373 (10%)	0.003	10,626 (3%)	10,718 (3%)	0.001	4,113 (1%)	4,131 (1%)	0.001	1,376 (0%)	1,472 (0%)	0.002
Pneumonia	8,573 (6%)	7,621 (5%)	0.027	11,355 (3%)	10,691 (3%)	0.010	6,651 (1%)	6,545 (1%)	0.002	5,144 (1%)	5,151 (1%)	0.001
Rheumatoid arthritis	3,066 (2%)	3,092 (2%)	0.002	6,198 (1%)	6,570 (2%)	0.007	2,355 (1%)	3,111 (1%)	0.021	1,201 (0%)	859 (0%)	0.012
Stroke	7,667 (5%)	7,047 (5%)	0.018	8,041 (2%)	8,794 (2%)	0.013	3,518 (1%)	3,293 (1%)	0.006	1,496 (0%)	1,305 (0%)	0.006
Venous thromboembolism	9,589 (6%)	9,241 (6%)	0.008	11,836 (3%)	12,475 (3%)	0.009	6,503 (1%)	8,075 (2%)	0.028	4,661 (1%)	2,441 (0%)	0.042

284 The 4 cohorts represent vaccine rollout periods.

285 ^aCalculated as the days of previous observation in the database before index date.

286 ^bAssessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

287 COVID-19 vaccination and post COVID-19 complications

- Table 2 shows the incidence of post COVID-19 VTE, ATE and HF, the 3 most common post
- 289 COVID-19 conditions among the studied. Outcome counts are presented separately for the
- 290 0-30, 31-90, 91-180, and 181-365 days after SARS-CoV-2 infection. Supplementary Tables
- 291 S27-37 include all studied complications, also for the different sensitivity and sub-analyses.
- 292 Similar incidence patterns were observed across all analyses: higher rates in the elderly
- 293 populations (cohort 1) and decreasing frequency with time after infection in all cohorts.

Cohort	Time window	Outcome	AURUM		COR	VA	GOL	D	SIDIAP	
Conort		Outcome	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
Cohort 1			N = 346,674	N = 552,602	N = 23,982	N = 26,736	N = 169,100	N = 118,507	N = 223,962	N = 89,941
	0 to 30 days	VTE	154 (4.44)	117 (2.12)	93 (38.78)	36 (13.46)	15 (0.89)	8 (0.68)	251 (11.21)	96 (10.67)
		ATE	57 (1.64)	70 (1.27)	128 (53.37)	50 (18.70)	8 (0.47)	7 (0.59)	350 (15.63)	208 (23.13)
		HF	135 (3.89)	198 (3.58)	439 (183.05)	199 (74.43)	21 (1.24)	9 (0.76)	1,205 (53.80)	640 (71.16)
	31 to 90 days	VTE	32 (0.92)	40 (0.72)	32 (13.34)	12 (4.49)	< 5	< 5	92 (4.11)	46 (5.11)
		ATE	15 (0.43)	43 (0.78)	33 (13.76)	23 (8.60)	< 5	< 5	222 (9.91)	130 (14.45)
		HF	72 (2.08)	113 (2.04)	143 (59.63)	86 (32.17)	8 (0.47)	8 (0.68)	493 (22.01)	298 (33.13)
	91 to 180 days	VTE	17 (0.49)	21 (0.38)	21 (8.76)	16 (5.98)	6 (0.35)	< 5	70 (3.13)	40 (4.45)
		ATE	23 (0.66)	28 (0.51)	31 (12.93)	25 (9.35)	< 5	6 (0.51)	200 (8.93)	112 (12.45)
		HF	61 (1.76)	95 (1.72)	164 (68.38)	115 (43.01)	< 5	5 (0.42)	432 (19.29)	252 (28.02)
	181 to 365 days	VTE	11 (0.32)	11 (0.20)	53 (22.10)	22 (8.23)	< 5	< 5	36 (1.61)	13 (1.45)
		ATE	14 (0.40)	23 (0.42)	56 (23.35)	41 (15.34)	< 5	< 5	124 (5.54)	53 (5.89)
		HF	54 (1.56)	58 (1.05)	281 (117.17)	199 (74.43)	< 5	6 (0.51)	235 (10.49)	149 (16.57)
Cohort 2			N = 1,975,726	N = 1,563,569	N = 34,317	N = 4,572	N = 583,399	N = 486,619	N = 433,151	N = 819,590
	0 to 30 days	VTE	345 (1.75)	220 (1.41)	88 (25.64)	8 (17.50)	42 (0.72)	24 (0.49)	404 (9.33)	400 (4.88)
		ATE	74 (0.37)	104 (0.67)	129 (37.59)	5 (10.94)	8 (0.14)	6 (0.12)	345 (7.96)	669 (8.16)
		HF	73 (0.37)	146 (0.93)	393 (114.52)	20 (43.74)	5 (0.09)	13 (0.27)	637 (14.71)	1,331 (16.24
	31 to 90 days	VTE	87 (0.44)	76 (0.49)	37 (10.78)	< 5	7 (0.12)	9 (0.18)	110 (2.54)	195 (2.38)
		ATE	39 (0.20)	93 (0.59)	33 (9.62)	< 5	7 (0.12)	9 (0.18)	205 (4.73)	444 (5.42)
		HF	50 (0.25)	103 (0.66)	152 (44.29)	10 (21.87)	5 (0.09)	7 (0.14)	274 (6.33)	643 (7.85)
	91 to 180 days	VTE	42 (0.21)	40 (0.26)	27 (7.87)	5 (10.94)	8 (0.14)	< 5	112 (2.59)	125 (1.53)
		ATE	33 (0.17)	43 (0.28)	29 (8.45)	< 5	5 (0.09)	< 5	185 (4.27)	417 (5.09)
		HF	32 (0.16)	69 (0.44)	171 (49.83)	14 (30.62)	< 5	< 5	228 (5.26)	579 (7.06)
	181 to 365 days	VTE	18 (0.09)	13 (0.08)	54 (15.74)	< 5	< 5	< 5	37 (0.85)	64 (0.78)

Table 2: Number of records (and risk per 10,000 individuals) for acute and subacute COVID-19 cardiac and thromboembolic complications, across cohorts and databases for any COVID-19 vaccination.

Cohort	Time window	Outcome	AUF	RUM	COR	IVA	GO	D	SID	AP
Conort	Time window	Outcome	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		ATE	14 (0.07)	18 (0.12)	62 (18.07)	5 (10.94)	< 5	< 5	112 (2.59)	178 (2.17)
		HF	22 (0.11)	35 (0.22)	286 (83.34)	17 (37.18)	< 5	< 5	111 (2.56)	246 (3.00)
Cohort 3			N = 1,510,401	N = 1,528,031	N = 96,423	N = 24,050	N = 417,996	N = 462,832	N = 869,497	N = 954,232
	0 to 30 days	VTE	268 (1.77)	142 (0.93)	122 (12.65)	8 (3.33)	32 (0.77)	17 (0.37)	425 (4.89)	180 (1.89)
		ATE	34 (0.23)	49 (0.32)	133 (13.79)	11 (4.57)	< 5	12 (0.26)	315 (3.62)	275 (2.88)
		HF	33 (0.22)	38 (0.25)	398 (41.28)	34 (14.14)	< 5	< 5	478 (5.50)	256 (2.68)
	31 to 90 days	VTE	61 (0.40)	46 (0.30)	46 (4.77)	8 (3.33)	< 5	7 (0.15)	120 (1.38)	92 (0.96)
		ATE	14 (0.09)	33 (0.22)	42 (4.36)	13 (5.41)	< 5	8 (0.17)	171 (1.97)	210 (2.20)
		HF	22 (0.15)	26 (0.17)	182 (18.88)	17 (7.07)	< 5	< 5	192 (2.21)	157 (1.65)
	91 to 180 days	VTE	29 (0.19)	26 (0.17)	46 (4.77)	9 (3.74)	5 (0.12)	< 5	101 (1.16)	101 (1.06)
		ATE	8 (0.05)	28 (0.18)	44 (4.56)	8 (3.33)	< 5	< 5	187 (2.15)	206 (2.16)
		HF	12 (0.08)	14 (0.09)	210 (21.78)	18 (7.48)	< 5	< 5	180 (2.07)	138 (1.45)
	181 to 365 days	VTE	< 5	11 (0.07)	79 (8.19)	16 (6.65)	< 5	< 5	45 (0.52)	26 (0.27)
		ATE	< 5	< 5	86 (8.92)	8 (3.33)	< 5	< 5	72 (0.83)	67 (0.70)
		HF	5 (0.03)	< 5	340 (35.26)	36 (14.97)	< 5	< 5	75 (0.86)	44 (0.46)
Cohort 4			N = 2,027,763	N = 2,085,598	N = 147,545	N = 22,245	N = 469,876	N = 550,437	N = 1,061,634	N = 880,950
	0 to 30 days	VTE	337 (1.66)	50 (0.24)	120 (8.13)	< 5	36 (0.77)	11 (0.20)	388 (3.65)	98 (1.11)
		ATE	26 (0.13)	8 (0.04)	121 (8.20)	10 (4.50)	< 5	< 5	268 (2.52)	95 (1.08)
		HF	28 (0.14)	< 5	370 (25.08)	18 (8.09)	< 5	< 5	430 (4.05)	75 (0.85)
	31 to 90 days	VTE	59 (0.29)	22 (0.11)	46 (3.12)	< 5	6 (0.13)	< 5	111 (1.05)	49 (0.56)
		ATE	12 (0.06)	9 (0.04)	40 (2.71)	< 5	< 5	< 5	142 (1.34)	76 (0.86)
		HF	14 (0.07)	9 (0.04)	167 (11.32)	16 (7.19)	< 5	< 5	160 (1.51)	47 (0.53)
	91 to 180 days	VTE	26 (0.13)	10 (0.05)	46 (3.12)	9 (4.05)	< 5	< 5	91 (0.86)	60 (0.68)
		ATE	< 5	6 (0.03)	33 (2.24)	12 (5.39)	< 5	< 5	153 (1.44)	90 (1.02)
		HF	10 (0.05)	< 5	187 (12.67)	13 (5.84)	< 5	< 5	172 (1.62)	55 (0.62)
	181 to 365 days	VTE	< 5	< 5	80 (5.42)	11 (4.94)	< 5	< 5	48 (0.45)	12 (0.14)

Cohort	Time window	Outcom	AURUM		CORIVA		GOLD		SIDIAP	
CONON	Time window	Outcome	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		ATE	< 5	< 5	72 (4.88)	10 (4.50)	< 5	< 5	53 (0.50)	28 (0.32)
		HF	< 5	< 5	312 (21.15)	15 (6.74)	< 5	< 5	61 (0.57)	15 (0.17)

296

297 The 4 cohorts represent vaccine rollout periods.

298 VTE = Venous thromboembolism (Deep vein thrombosis + Pulmonary embolism), ATE = Arterial thromboembolism (Ischemic stroke + Transient ischemic attack + Myocardial infarction), HF =

299 Heart failure

300 Results from calibrated estimates pooled in meta-analysis across cohorts and databases are

301 shown in Figure 2.

- 302 Protective effects of vaccination are observed against acute post COVID-19 VTE, DVT, and PE:
- 303 meta-analytic sHR of 0.34 (95% CI, 0.27-0.44); 0.51 (0.42-0.62); and 0.30 (0.22-0.41)
- respectively. The protective effects persisted for subacute VTE: sHR of 0.58 (0.48-0.69), 0.64
- 305 (0.50-0.82) and 0.54 (0.41-0.72) for 31-90, 91-180, and 181-365 days post COVID-19,
- 306 respectively. Protection effects of vaccine against these outcomes were observed across
- 307 databases and cohorts, see Supplementary Figures S16-24.
- 308 Similarly, the risk of ATE, IS and MI in the acute phase after infection was reduced in the

309 vaccinated, sHR of 0.62 (0.49-0.77), 0.63 (0.45-0.90), and 0.71 (0.58-0.85) respectively.

Protection persisted for subacute ATE and IS in the 181-365 days post COVID-19 (sHR of 0.68

311 (0.55-0.84) and 0.70 (0.51-0.96)), and no effect was seen in the 30-180 days window.

Vaccination effect on post COVID-19 TIA was only seen in the 181-365 days, sHR of 0.56

- 313 (0.37-0.86). Supplementary Figures S25-33 show database- and cohort-specific estimates
- 314 for ATE related complications.

Risk of post COVID-19 cardiac complications was reduced in vaccinated individuals. Meta-

analytic estimates in the acute phase showed sHR of 0.58 (0.50-0.70) for HF, 0.51 (0.34-0.77)

for MP, and 0.63 (0.44, 0.89) for VACA. Protective effects persisted for subacute post COVID-

318 19 HF: sHR 0.71 (0.59-0.85) for 31-90 days, 0.68 (0.56-0.82) for 91-180 days, and 0.57 (0.44-

- 0.72) for 181-365 days. For subacute MP, risk was only lowered in the 31-90 days post
- 320 infection, sHR 0.55 (0.31-0.99), and no effect was seen for subacute VACA. Protection
- against post COVID-19 HS was only seen in the 91-180 days after infection, s, of 0.54 (0.29-

- 322 0.99). Database- and cohort-specific results for these cardiac diseases are in Supplementary
- 323 Figures S34-42.
- 324 Stratified analyses by vaccine brand showed similar associations, except for ChAdOx1 which
- 325 was not associated with reduced VTE risk in the subacute window. Sensitivity analyses were
- 326 consistent with main results, see Supplementary Figures S8-15.





Figure 2: Forest plots for vaccine effectiveness (any COVID-19 vaccine), meta-analysis across cohorts and databases. Dashed line
 represents a level of heterogeneity I2 > 0.4.

330 VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Haemorrhagic stroke

- 331 Figure 3 shows the results of comparative effects of BNT162b2 vs ChAdOx1, based on UK
- data. Meta-analytic estimates favoured BNT162b2 (sHR of 0.66 (0.46, 0.93)) for VTE in the 0-
- 333 30 days after infection, but no differences were seen for subacute VTE or for any of the
- other outcomes. Results from sensitivity analyses, database- and cohort-specific estimates
- were in line with the main approach, see Supplementary Figures S43-53.



336 Figure 3: Forest plots for comparative vaccine effect (BNT162b2 vs. ChAdOx1), meta-analysis across cohorts and databases.



339 **Discussion**

340 Key findings

- 341 Our analyses showed a substantial reduction of risk (38-66%) for thromboembolic and
- 342 cardiac events in the acute phase of COVID-19 associated with vaccination. This finding was
- 343 consistent across four databases and three different European countries. Risks for subacute
- post COVID-19 VTE and HF were also reduced, but to a lesser extent (29-46%).
- 345 The risks of post COVID-19 ATE, MP, and VACA were also reduced in vaccinated persons, but
- 346 only in the acute phase.

347 **Results in context**

- 348 The relationship between SARS-CoV-2 infection, COVID-19 vaccines, and thromboembolic
- 349 and/or cardiac complications is tangled. Some large studies have found an increased risk of
- 350 VTE and ATE following both ChAdOx1 and BNT162b2 vaccination (17,43). However, other
- 351 studies have not identified such risk (44). It is worth noting that an elevated risk of VTE has
- also been reported among patients with COVID-19, and its occurrence can lead to poor
- prognosis and mortality (45–47). Similarly, several observational studies have found an
- association between COVID-19 mRNA vaccination and a short-term increased risk of
- myocarditis, particularly among younger male individuals (13–16,48–50). For instance, a self-
- 356 controlled case series study conducted in England revealed about 30% increased risk of
- hospital admission due to myocarditis within 28 days following both ChAdOx1 and
- BNT162b2 vaccines. However, this same study also found a 9-fold higher risk for myocarditis
- following a positive SARS-CoV-2 test, clearly offsetting the observed post-vaccine risk.

medRxiv preprint doi: https://doi.org/10.1101/2023.06.28.23291997; this version posted June 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

360	COVID-19 vaccines have demonstrated high efficacy and effectiveness in preventing
361	infection and reducing the severity of acute-phase infection. However, with the emergence
362	of newer variants of the virus, such as the Omicron variant (51), and the waning protective
363	effect of the vaccine over time (52), there is a growing interest in understanding whether the
364	vaccine can also reduce the risk of complications after breakthrough infections. Our study
365	demonstrates that vaccination may help mitigate the risk of thromboembolic and cardiac
366	events associated with SARS-CoV-2, including breakthrough infections.
367	Recent studies suggested that COVID-19 vaccination could potentially protect against acute
368	post COVID-19 cardiac and thromboembolic events (22–24). For example, in a large
369	prospective cohort study, Xie et. al (2022) (22) found the risk of VTE after SARS-CoV-2
370	infection was largely attenuated in the fully vaccinated ambulatory patients (about 21-fold
371	and 6-fold after non-vaccinated and breakthrough infection, respectively).
372	While the effect of vaccination on subacute post COVID-19 conditions has been studied,
373	(23,24,53–59), there has been limited reporting on the condition-specific risks associated
374	with COVID-19, even though the prognosis for different complications can vary significantly.
374 375	with COVID-19, even though the prognosis for different complications can vary significantly. In line with previous studies, our findings suggest a potential benefit of vaccination in
375	In line with previous studies, our findings suggest a potential benefit of vaccination in
375 376	In line with previous studies, our findings suggest a potential benefit of vaccination in reducing the risk of post COVID-19 thromboembolic and cardiac complications. We included
375 376 377	In line with previous studies, our findings suggest a potential benefit of vaccination in reducing the risk of post COVID-19 thromboembolic and cardiac complications. We included broader populations, estimated the risk in both acute and subacute infection phases and
375 376 377 378	In line with previous studies, our findings suggest a potential benefit of vaccination in reducing the risk of post COVID-19 thromboembolic and cardiac complications. We included broader populations, estimated the risk in both acute and subacute infection phases and replicated these using four large independent observational databases. By pooling results
375 376 377 378 379	In line with previous studies, our findings suggest a potential benefit of vaccination in reducing the risk of post COVID-19 thromboembolic and cardiac complications. We included broader populations, estimated the risk in both acute and subacute infection phases and replicated these using four large independent observational databases. By pooling results across different settings, we provided the most up-to-date and robust evidence on this topic.

383	robustness and replicability of our findings. All databases had complete recordings of
384	vaccination status (date and brand). Algorithms to identify study outcomes were used in
385	previous published network studies, including regulatory-funded research (6,8,19,31). The
386	staggered cohort design and methods used are yet another strength of our study, as recent
387	research has demonstrated the validity of this design to minimise bias (35).
388	Our study also has limitations. First, the use of real-world data comes with inherent
389	limitations including data quality issues and risk of confounding (60). To address these
390	limitations, we employed state-of-the-art methods, including large-scale propensity score
391	weighting and calibration of effect estimates using NCO (35,41). A recent study (61) has
392	demonstrated that methodologically sound observational studies based on routinely
393	collected data can produce similar results to clinical trials. Another limitation is potential
394	misclassification: Asymptomatic and mild COVID-19 infections may have not been recorded
395	and post COVID-19 outcomes of interest may be under-recorded in primary care databases
396	(CPRD AURUM and GOLD) without hospital linkage. However, results in SIDIAP and CORIVA
397	which include secondary care data were similar.

398 **Conclusions**

Vaccination against SARS-CoV-2 substantially reduced the risk of acute post COVID-19
thromboembolic and cardiac complications, likely through a reduction in the severity of
COVID-19 disease due to vaccine-induced immunity. These protective effects lasted for up to
one year for post COVID-19 VTE, but not clearly for other complications. Further research is
needed on the possible waning of these protective effects over time, and on the impact of
booster vaccination to regain these potential benefits.

405 **References**

406	1.	Wu N, Joyal-Desmarais K, Ribeiro PAB, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term
407		effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in
408		adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to
409		December, 2022. Lancet Respir Med. 2023 May;11(5):439–52.
410	2.	Lau JJ, Cheng SMS, Leung K, Lee CK, Hachim A, Tsang LCH, et al. Real-world COVID-19 vaccine
411		effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
412		Nat Med. 2023 Feb 18;29(2):348–57.
413	3.	Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD, et al. Impact of
414		vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 2021 Aug
415		9;27(8):1370–8.
416	4.	Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in
417		health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against
418		infection (SIREN): a prospective, multicentre, cohort study. The Lancet. 2021
419		May;397(10286):1725–35.
420	5.	Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity
421		of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha
422		SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022 Mar
423		9;e069761.
424	6.	Burn E, Li X, Delmestri A, Jones N, Duarte-Salles T, Reyes C, et al. Thrombosis and
425		thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United
426		Kingdom. Nat Commun. 2022 Nov 23;13(1):7167.
427	7.	Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous
428		thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-
429		AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021
430		May 5;n1114.
431	8.	Li X, Burn E, Duarte-Salles T, Yin C, Reich C, Delmestri A, et al. Comparative risk of thrombosis
432		with thrombocytopenia syndrome or thromboembolic events associated with different covid-
433		19 vaccines: international network cohort study from five European countries and the US.
434		BMJ. 2022 Oct 26;e071594.

435 436 437	9.	Simpson CR, Shi T, Vasileiou E, Katikireddi S V., Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med. 2021 Jul 9;27(7):1290–7.
438 439 440	10.	Lee E, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021 May 9;96(5):534– 7.
441 442 443	11.	Abraham N, Spruin S, Rossi T, Fireman B, Zafack J, Blaser C, et al. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines. Vaccine. 2022 Jul 30;40(32):4663–71.
444 445 446	12.	Lai FTT, Li X, Peng K, Huang L, Ip P, Tong X, et al. Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine. Ann Intern Med. 2022 Mar;175(3):362–70.
447 448 449	13.	Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022 Feb 14;28(2):410–22.
450 451 452	14.	Husby A, Hansen JV, Fosbøl E, Thiesson EM, Madsen M, Thomsen RW, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021 Dec 16;e068665.
453 454 455	15.	Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. 2022 Jun 1;7(6):600.
456 457 458	16.	Simone A, Herald J, Chen A, Gulati N, Shen AYJ, Lewin B, et al. Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med. 2021 Dec 1;181(12):1668.
459 460 461	17.	Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021 Aug 26;n1931.
462 463 464 465	18.	Voss EA, Shoaibi A, Yin Hui Lai L, Blacketer C, Alshammari T, Makadia R, et al. Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. EClinicalMedicine. 2023 Apr;58:101932.

466 467 468	19.	Burn E, Duarte-Salles T, Fernandez-Bertolin S, Reyes C, Kostka K, Delmestri A, et al. Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study. Lancet Infect Dis. 2022 Aug;22(8):1142–52.
469 470 471	20.	Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S, et al. Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales. Circulation. 2022 Sep 20;146(12):892–906.
472 473	21.	Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022 Mar 7;28(3):583–90.
474 475 476	22.	Xie J, Prats-Uribe A, Feng Q, Wang Y, Gill D, Paredes R, et al. Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19. JAMA Intern Med. 2022 Oct 1;182(10):1063.
477 478	23.	Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022 Jul 25;28(7):1461–7.
479 480 481	24.	Kim YE, Huh K, Park YJ, Peck KR, Jung J. Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection. JAMA. 2022 Sep 6;328(9):887.
482 483 484	25.	Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019 Dec 1;48(6):1740– 1740g.
485 486	26.	Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015 Jun;44(3):827–36.
487 488 489	27.	García-Gil MDM, Hermosilla E, Prieto-Alhambra D, Fina F, Rosell M, Ramos R, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care. 2011;19(3):135–45.
490 491 492 493	28.	Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association. 2015 May 1;22(3):553– 64.
494 495 496	29.	Martí Català, Núria Mercadé-Besora, Raivo Kolde, Nhung TH Trinh, Elena Roel, Edward Burn, et al. The Effectiveness of COVID-19 Vaccines to Prevent Long COVID Symptoms: Staggered Cohort Analyses of Data from the UK, Spain, and Estonia. SSRN.

497	30.	Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S, et al. Association of COVID-19 With
498		Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48
499		Million Adults in England and Wales. Circulation. 2022 Sep 20;146(12):892–906.
500	31.	Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the
501		background incidence rates of adverse events of special interest for covid-19 vaccines in eight
502		countries: multinational network cohort study. BMJ. 2021 Jun 14;n1435.
503	32.	Prieto-Alhambra D, Kostka K, Duarte-Salles T, Prats-Uribe A, Sena A, Pistillo A, et al. Unraveling
504		COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS. Res
505		Sq. 2021 Mar 1;
506	33.	Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding
507		and bias in observational studies. Epidemiology. 2010 May;21(3):383–8.
508	34.	Li X, Lai LYH, Ostropolets A, Arshad F, Tan EH, Casajust P, et al. Bias, precision and timeliness of
509		historical (background) rate comparison methods for vaccine safety monitoring: an empirical
510		multi-database analysis. Front Pharmacol. 2021;12:773875.
511	35.	Català M, Burn E, Rathod-Mistry T, Xie J, Delmestri A, Prieto-Alhambra D, et al. Observational
512		methods for COVID-19 vaccine effectiveness research: a trial emulation and empirical
513		evaluation. medRxiv [Internet]. 2022 Jan 1;2022.11.09.22282065. Available from:
514		http://medrxiv.org/content/early/2022/11/17/2022.11.09.22282065.abstract
515	36.	Li F, Morgan KL, Zaslavsky AM. Balancing Covariates via Propensity Score Weighting. J Am Stat
516		Assoc. 2018 Jan 2;113(521):390–400.
517	37.	Coronavirus (COVID-19) in the UK [Internet]. [cited 2022 Dec 15]. Available from:
518		https://coronavirus.data.gov.uk/
519	38.	Generalitat de Catalunya. Dades COVID [Internet]. [cited 2022 Jan 15]. Available from:
520		https://dadescovid.cat/
521	39.	Nguyen TL, Collins GS, Spence J, Daurès JP, Devereaux PJ, Landais P, et al. Double-adjustment
522		in propensity score matching analysis: choosing a threshold for considering residual
523		imbalance. BMC Med Res Methodol. 2017 Dec 28;17(1):78.
524	40.	Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J
525		Am Stat Assoc. 1999 Jun;94(446):496–509.

526 527 528	41.	Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proceedings of the National Academy of Sciences. 2018 Mar 13;115(11):2571–7.
529	42.	Serghiou S, Goodman SN. Random-Effects Meta-analysis. JAMA. 2019 Jan 22;321(3):301.
530 531	43.	Elkin PL, Brown SH, Resendez S, McCray W, Resnick M, Hall K, et al. COVID-19 vaccination and venous thromboembolism risk in older veterans. J Clin Transl Sci. 2023 Feb 1;7(1):e55.
532 533 534	44.	Houghton DE, Wysokinski W, Casanegra AI, Padrnos LJ, Shah S, Wysokinska E, et al. Risk of venous thromboembolism after COVID-19 vaccination. Journal of Thrombosis and Haemostasis. 2022 Jul;20(7):1638–44.
535 536 537	45.	Katsoularis I, Fonseca-Rodríguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022 Apr 6;e069590.
538 539 540	46.	Fang MC, Reynolds K, Tabada GH, Prasad PA, Sung SH, Parks AL, et al. Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19. JAMA Netw Open. 2023 Mar 13;6(3):e232338.
541 542 543	47.	Lee Y, Jehangir Q, Li P, Gudimella D, Mahale P, Lin CH, et al. Venous thromboembolism in COVID-19 patients and prediction model: a multicenter cohort study. BMC Infect Dis. 2022 Dec 13;22(1):462.
544 545 546	48.	Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. 2022 Jun 1;7(6):600.
547 548 549	49.	Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. New England Journal of Medicine. 2021 Dec 2;385(23):2132–9.
550 551 552	50.	Wong HL, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. The Lancet. 2022 Jun;399(10342):2191–9.
553 554 555	51.	Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine. 2022 Apr 21;386(16):1532–46.

556	52.	Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and
557		effectiveness and side-effects of boosters: a prospective community study from the ZOE
558		COVID Study. Lancet Infect Dis. 2022 Jul;22(7):1002–10.
559	53.	Zisis SN, Durieux JC, Mouchati C, Perez JA, McComsey GA. The Protective Effect of Coronavirus
560		Disease 2019 (COVID-19) Vaccination on Postacute Sequelae of COVID-19: A Multicenter
561		Study From a Large National Health Research Network. Open Forum Infect Dis. 2022 Jul
562		4;9(7).
563	54.	Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine
564		versus no vaccination on symptoms of patients with long covid: target trial emulation based
565		on ComPaRe e-cohort. BMJ Medicine. 2023 Feb 28;2(1):e000229.
566	55.	Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long
567		covid: systematic review. BMJ Medicine. 2023 Feb;2(1):e000385.
568	56.	Ioannou GN, Baraff A, Fox A, Shahoumian T, Hickok A, O'Hare AM, et al. Rates and Factors
569		Associated With Documentation of Diagnostic Codes for Long COVID in the National Veterans
570		Affairs Health Care System. JAMA Netw Open. 2022 Jul 29;5(7):e2224359.
571	57.	Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. Association Between
572		BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in
573		Health Care Workers. JAMA. 2022 Aug 16;328(7):676.
574	58.	Brannock MD, Chew RF, Preiss AJ, Hadley EC, Redfield S, McMurry JA, et al. Long COVID risk
575		and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nat
576		Commun. 2023 May 22;14(1):2914.
577	59.	Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. Risk Factors
578		Associated With Post-COVID-19 Condition. JAMA Intern Med. 2023 Mar 23;
579	60.	Yuan H, Ali MS, Brouwer ES, Girman CJ, Guo JJ, Lund JL, et al. Real-World Evidence: What It Is
580		and What It Can Tell Us According to the International Society for Pharmacoepidemiology
581		(ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG). Clin Pharmacol
582		Ther. 2018 Aug;104(2):239–41.
583	61.	Wang S V., Schneeweiss S, Franklin JM, Desai RJ, Feldman W, Garry EM, et al. Emulation of
584		Randomized Clinical Trials With Nonrandomized Database Analyses. JAMA. 2023 Apr
585		25;329(16):1376.

586

588 Article Information

589 Corresponding author

- 590 Prof. Daniel Prieto-Alhambra
- 591 Botnar Research Centre, Windmill Road, OX3 7LD, Oxford, United Kingdom

592 Author Contributions:

- 593 DPA and AMJ led the conceptualisation of the study with contributions from MC and NMB.
- 594 AMJ, TDS, ER, AU and NT adapted the study design with respect to the local vaccine rollouts.
- 595 AD and WM mapped and curated CPRD data. MC and NMB developed code with
- 596 methodological contributions advice from MTSS and CP. DPA, MC, NT, TDS, HE, XL, CR, and
- 597 AMJ clinically interpreted the results. NMB, XL, AMJ and DPA wrote the first draft of the
- 598 manuscript, and all authors read, revised, and approved the last version. DPA and AMJ
- 599 obtained the funding for this research.

600 Ethics

- 601 The study was approved by the CPRD's Research Data Governance Process, Protocol No
- 602 21_000557 and the Clinical Research Ethics committee of Fundació Institut Universitari per a
- 603 la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol) (approval number
- 4R22/133) and the Research Ethics Committee of the University of Tartu (approval No.
- 605 330/T-10).

606 Disclosures

607 DPA's department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis,

and UCB Biopharma, the European Medicines Agency and the Innovative Medicines

609	Initiative. His research group has received consultancy fees from Astra Zeneca and UCB
610	Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma
611	have funded or supported training programmes organised by DPA's department. RK's
612	research group has received consultancy fees from AstraZeneca, and the Estonian Ministry
613	of Social Affairs through the RITA CORIVA and RITA MAITT projects. AU reports funding from
614	the European Regional Development Fund (RITA 1/02-120) for her institution. HN reports
615	support from the European Health Data & Evidence Network (EHDEN) project grant,
616	Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968 for
617	harmonization of the Norwegian registry data into OMOP CDM. TDS reports funding from
618	the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No
619	806968 for the institute to map the SIDIAP data to the OMOP CDM. The JU receives support
620	from the European Union's Horizon 2020 research and innovation programme and EFPIA. All
621	other authors declare no conflict of interest.
622	Funding/Support
623	The research was supported by the National Institute for Health and Care Research (NIHR)
624	Oxford Biomedical Research Centre (BRC).

DPA is funded through a NIHR Senior Research Fellowship (Grant number SRF-2018–11-ST2-004).

- 627 Funding to perform the study in the SIDIAP database was provided by the Real World
- 628 Epidemiology (RWEpi) research group at IDIAPJGol.
- 629 Costs of databases mapping to OMOP CDM were covered by the European Health Data and
- 630 Evidence Network (EHDEN).

631 Role of the Funder/Sponsor

- The funders had no role in the design and conduct of the study; interpretation of the data;
- 633 preparation of the manuscript; and decision to submit it for publication.
- 634 Data Sharing Statement
- 635 CPRD: CPRD data were obtained under the CPRD multi-study license held by the University
- 636 of Oxford after Research Data Governance (RDG) approval. Direct data sharing is not
- 637 allowed.
- 638 <u>SIDIAP</u>: In accordance with current European and national law, the data used in this study is
- only available for the researchers participating in this study. Thus, we are not allowed to
- 640 distribute or make publicly available the data to other parties. However, researchers from
- 641 public institutions can request data from SIDIAP if they comply with certain requirements.
- 642 Further information is available online (<u>https://www.sidiap.org/index.php/menu-</u>
- 643 <u>solicitudesen/application-proccedure</u>) or by contacting SIDIAP (sidiap@idiapjgol.org).
- 644 <u>CORIVA</u>: CORIVA data were obtained under the approval of Research Ethics Committee of
- 645 the University of Tartu and the patient level data sharing is not allowed.

646 Acknowledgements

- 647 This study is based in part on data from the Clinical Practice Research Datalink obtained
- 648 under license from the UK Medicines and Healthcare products Regulatory Agency. We thank
- the patients who provided these data, and the NHS who collected the data as part of their
- 650 care and support. All interpretations, conclusions and views expressed in this publication are
- those of the authors alone and not necessarily those of CPRD.

- 652 We would also like to thank the healthcare professionals in the Catalan healthcare system
- 653 involved in the management of COVID-19 during these challenging times, from primary care
- to intensive care units; the Institut de Català de la Salut and the Program d'Analítica de
- Dades per a la Recerca i la Innovació en Salut for providing access to the different data
- 656 sources accessible through SIDIAP.